Clinical guideline
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Thyroid · 2025
Studies and guidelines: Thyroid cancer
20 items with a structured summary · Thyroid cancer: the complete guide
Clinical guideline
The 2023 Bethesda System for Reporting Thyroid Cytopathology
Thyroid® · 2023
6 categoriesNumber of diagnostic categories
Clinical guideline
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Thyroid® · 2021
31 recommendationsNumber of recommendations
Clinical guideline
ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
Journal of the American College of Radiology · 2017
Clinical guideline
Screening for Thyroid Cancer
JAMA · 2017
4.5% per yearAnnual increase in detected thyroid cancer incidence over the past 10 years
Clinical guideline
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid® · 2016
Clinical guideline
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Thyroid® · 2015
67 recommendationsNumber of evidence-based recommendations
Review article
Thyroid cancer
The Lancet · 2023
Clinical trial · Phase 2
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Annals of Oncology · 2022
56%Investigator-assessed objective response rate (ORR)
Review article
Overview of the 2022 WHO Classification of Thyroid Neoplasms
Endocr Pathol · 2022
Divided into benign, low-risk and malignantFollicular cell-derived neoplasms
Clinical trial · Phase 3
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
N Engl J Med · 2015
18.3 months vs 3.6 monthsMedian progression-free survival
Other
The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries
Thyroid · 2015
≥60% of casesProportion attributable to diagnostic changes in women younger than 80 years (2003 to 2007): France, Italy, the United States, Australia and Korea
Observational study
Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation
Thyroid® · 2014
18 to 227 monthsDuration of observation
Clinical trial · Phase 3
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
The Lancet · 2014
10.8 vs 5.8 months (sorafenib vs placebo)Median progression-free survival
Clinical trial · Phase 3
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
J Clin Oncol · 2012
Not reached (Weibull model prediction: 30.5 months) vs 19.3 monthsMedian progression-free survival
Clinical trial · Phase 3
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial
Lancet · 2025
97.9% (no ablation) vs 96.3% (ablation)5-year recurrence-free survival (ITT)
Clinical trial · Phase 3
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
N Engl J Med · 2022
95.6% (no radioiodine) vs 95.9% (radioiodine)Patients without an event at 3 years
Clinical trial · Phase 3
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer
N Engl J Med · 2012
85.0% vs 88.9%Ablation success: low dose vs high dose
Clinical trial · Phase 3
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
N Engl J Med · 2023
Not reached vs 16.8 monthsMedian progression-free survival
Clinical trial · Phase 2
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
J Clin Oncol · 2018
69% (11 of 16 patients)Confirmed overall response rate (initial report)
Nothing found.